Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Tryptamine Therapeutics ( (AU:ENP) ).
Entropy Neurodynamics Limited has lodged an application with the ASX for the quotation of 600,000 new ordinary fully paid shares, with an issue date of March 13, 2026. The move modestly increases the company’s listed share capital and may provide additional liquidity in its stock, although the filing offers no detail on the purpose of the issuance or its impact on existing shareholders.
The application confirms the company’s compliance with ASX Listing Rules for quoting the new securities, indicating these shares arise from the exercise or conversion of existing options or other convertible securities. While the scale of the issuance appears relatively limited, it signals ongoing capital-structure activity that stakeholders may monitor for future dilution, funding initiatives or strategic developments.
The most recent analyst rating on (AU:ENP) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.
More about Tryptamine Therapeutics
Entropy Neurodynamics Limited is an Australia-based company listed on the ASX under the code ENP. The filing does not specify its industry, products or services, but confirms its status as a listed entity seeking quotation of additional ordinary fully paid shares on the Australian market.
Average Trading Volume: 2,462,861
Technical Sentiment Signal: Sell
Current Market Cap: A$54.97M
See more insights into ENP stock on TipRanks’ Stock Analysis page.